Esperion to Present at J.P. Morgan Healthcare Conference

Event summary

  • Esperion will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025.
  • The presentation and fireside chat will begin at 2:15 PM PT / 5:15 PM ET.
  • A webcast of the presentation will be available on Esperion’s website.
  • Esperion markets two oral, once-daily, non-statin therapies for cardiovascular disease.

The big picture

Esperion’s participation in J.P. Morgan’s Healthcare Conference signals an effort to bolster investor confidence and potentially attract partnerships. The company’s focus on ACLY biology and its commercial infrastructure positions it as a potential acquisition target or partner for larger pharmaceutical companies seeking U.S. market access, though the success of this strategy remains to be seen. The conference provides a platform to articulate this value proposition to a broad audience of institutional investors.

What we're watching

Pipeline Diversification
The conference presentation will likely highlight Esperion’s pipeline beyond its current marketed therapies, particularly its efforts in Primary Sclerosing Cholangitis and renal diseases, which will be scrutinized for potential revenue contribution.
Commercial Strategy
Esperion’s stated ambition to be a partner-of-choice for global innovators seeking U.S. market access will be tested by investor sentiment regarding the viability of this strategy and its impact on margins.
Global Reach
The company's global approvals across more than 40 countries suggest a broad international footprint; however, the sustainability of this expansion and its contribution to overall revenue will be a key area of investor focus.